Diginex launches supply chain due diligence solution
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/26/2026
- Nasdaq lags on angst over AI spending ahead of earnings reports
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil falls on report China pushing for end US-Iran war
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- FDA approves Tylenol with Naproxen as first OTC combo pain reliever
- AMD (AMD) PT Raised to $1,250 at Baird
- Pakistan, Iran explore path towards new talks with US in a China-initiated push, sources say
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Nasdaq lags on angst over AI spending ahead of earnings reports
Diginex Expands Supply Chain End-to-End Product Suite Amid Accelerating Regulatory Pressure
June 4, 2026 8:00 AM EDTIn a human rights and supply chain due diligence market valued at approximately $3.8 billion in 2025, non-compliance carries material, financial and reputational consequences.
Diginexs Risk-to-Remedy is an end-to-end solution supporting supply chain transparency and risk surfacing to enable faster, evidence-based action and more defensible reporting.
Upcoming enhancements to Diginexs supply chain offering will enable businesses to make smarter decisions, take effective action and measure outcomes.
LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Diginex Limited (Nasdaq: DGNX), a provider of ESG,... More
